Spannagl M, Hoffmann H, Siebeck M, Weipert J, Schwarz H P, Schramm W
Department of Medicine, Ludwig-Maximilians University, Munich, FRG.
Thromb Res. 1991 Jan 1;61(1):1-10. doi: 10.1016/0049-3848(91)90163-q.
Inhibition of activated clotting factors is an important therapeutic approach in disseminated intravascular coagulation (DIC). We examined the possible protective effect of a purified complex of human antithrombin III (AT III) and heparin in endotoxin-induced DIC in pigs. Two groups of endotoxemic pigs were studied. AT III-heparin group pigs (n = 8) were pretreated with a bolus injection of 500 units AT III-heparin complex, followed by a continuous infusion of 1000 units of the complex for 6 hours given simultaneously with the infusion of 10 micrograms/kgh of S. abortus equi endotoxin. Controls (n = 9) were given saline in addition to the continuous infusion of endotoxin. AT III activity, prothrombin and soluble fibrin in plasma were determined by chromogenic substrate methods. Fibrinogen was measured turbidimetrically. Human AT III antigen in the treated group was 64 +/- 3% at 2 hours and increased to 84 +/- 4% until the end of the experiment. AT III activity in the AT III-heparin group was elevated throughout the whole observation period (greater than 100%), whereas it was significantly lower in the controls. Prothrombin decreased similarly in both groups by approximately 35% until the end of the experiment. AT III-heparin treatment significantly attenuated the endotoxin-induced consumption of fibrinogen and completely prevented the increase in soluble fibrin in plasma. However, no significant effect of AT III-heparin was observed on endotoxin-induced mortality and dysfunction in pulmonary gas exchange. Therefore we conclude that the purified AT III-heparin complex inhibits thrombin effects and prevents development of DIC, but fails to significantly influence clinical outcome in endotoxin shock of the pig.
抑制活化凝血因子是弥散性血管内凝血(DIC)的一种重要治疗方法。我们研究了纯化的人抗凝血酶III(AT III)与肝素复合物对内毒素诱导的猪DIC可能的保护作用。研究了两组内毒素血症猪。AT III-肝素组猪(n = 8)先静脉推注500单位AT III-肝素复合物进行预处理,随后持续输注1000单位该复合物6小时,同时输注10微克/千克的马流产沙门氏菌内毒素。对照组(n = 9)除持续输注内毒素外还给予生理盐水。采用发色底物法测定血浆中AT III活性、凝血酶原和可溶性纤维蛋白。用比浊法测定纤维蛋白原。治疗组2小时时人AT III抗原为64±3%,至实验结束时升至84±4%。AT III-肝素组在整个观察期内AT III活性均升高(大于100%),而对照组则显著降低。两组凝血酶原均类似地下降约35%直至实验结束。AT III-肝素治疗显著减轻了内毒素诱导的纤维蛋白原消耗,并完全阻止了血浆中可溶性纤维蛋白的增加。然而,未观察到AT III-肝素对内毒素诱导的死亡率和肺气体交换功能障碍有显著影响。因此我们得出结论,纯化的AT III-肝素复合物可抑制凝血酶作用并预防DIC的发展,但未能显著影响猪内毒素休克的临床结局。